Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in ... Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia ...
Nov. 12, 2013 - PR Newswire via Yahoo! Finance